200 related articles for article (PubMed ID: 21537048)
1. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Naqvi K; Garcia-Manero G; Sardesai S; Oh J; Vigil CE; Pierce S; Lei X; Shan J; Kantarjian HM; Suarez-Almazor ME
J Clin Oncol; 2011 Jun; 29(16):2240-6. PubMed ID: 21537048
[TBL] [Abstract][Full Text] [Related]
2. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
Daver N; Naqvi K; Jabbour E; Kadia T; DiNardo C; Cardenas-Turanzas M; Pierce S; Nguyen KT; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Am J Hematol; 2014 May; 89(5):509-16. PubMed ID: 24458781
[TBL] [Abstract][Full Text] [Related]
3. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
5. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
6. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Fega KR; Abel GA; Motyckova G; Sherman AE; DeAngelo DJ; Steensma DP; Galinsky I; Wadleigh M; Stone RM; Driver JA
J Geriatr Oncol; 2015 Jul; 6(4):288-98. PubMed ID: 26073533
[TBL] [Abstract][Full Text] [Related]
7. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Komrokji RS; Corrales-Yepez M; Al Ali N; Kharfan-Dabaja M; Padron E; Fields T; Lancet JE; List AF
Cancer; 2012 May; 118(10):2659-64. PubMed ID: 21956402
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
[TBL] [Abstract][Full Text] [Related]
9. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.
Sevindik OG; Guc Z; Kahraman S; Medeni Solmaz S; Katgi A; Acar C; Alacacioglu I; Piskin O; Ozsan GH; Demirkan F; Undar B; Ozcan MA
Leuk Lymphoma; 2015; 56(9):2552-5. PubMed ID: 25669924
[TBL] [Abstract][Full Text] [Related]
10. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
11. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Zipperer E; Pelz D; Nachtkamp K; Kuendgen A; Strupp C; Gattermann N; Haas R; Germing U
Haematologica; 2009 May; 94(5):729-32. PubMed ID: 19336740
[TBL] [Abstract][Full Text] [Related]
12. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
15. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
16. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
[TBL] [Abstract][Full Text] [Related]
17. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
18. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
20. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]